JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $16
CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating
CureVac Analyst Ratings
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $16
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $16
CureVac's Promising Cancer Vaccine Candidate CVGBM Elicits Buy Rating
Deutsche Bank Maintains CureVac(CVAC.US) With Hold Rating, Cuts Target Price to $3.9
CureVac (CVAC) Receives a Hold From Deutsche Bank
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)
CureVac Analyst Ratings
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Cuts Target Price to $16
CureVac: A Buy Rating Amidst Intellectual Property Litigation and Strong Valuation Metrics
Analysts' Opinions Are Mixed on These Healthcare Stocks: CureVac (CVAC), Insmed (INSM) and Quest Diagnostics (DGX)
CureVac Analyst Ratings
CureVac's Strategic Realignment and Positive Financial Outlook Prompt Buy Rating
Buy Rating on CureVac: Positive Financial Outlook and Promising Vaccine Trials Fuel Optimism
Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Revance Therapeutics (RVNC) and CureVac (CVAC)
Deutsche Numis Keeps Their Hold Rating on CureVac (CVAC)
CureVac Analyst Ratings
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)